Stellar Biotech is the industry
leader in the field of sustainably manufacturable Keyhole Limpet Hemocyanin, or
KLH, a revolutionary pharmaceutical protein derived from a scarce species of
limpet that only lives in the northeast Pacific, Megathura crenulata, more commonly
known as the great or giant keyhole limpet. The exceedingly complex structure
and size of the KLH molecule has placed it well beyond the capabilities of even
the most advanced synthetic production technologies, meaning the only source
for this extremely useful carrier protein is this scarce organism, which lives
in only one region of the earth’s waters, an increasingly endangered ocean
habitat. KLH is already in use across a wide variety of both research and
therapeutic vaccine applications whenever developers can get their hands on
enough of the stuff, due to a significant litany of advantages offered by the
molecule which simply cannot be found elsewhere or replicated using synthetic
alternatives.
What really sets Stellar apart
within this niche industry is their world-leading, proprietary aquaculture
technology that allows them to sustainably farm giant keyhole limpets and
extract an abundant supply of GMP-grade Stellar KLH™ without harming the
organism. KLH is eagerly sought after for its ability to carry peptides,
typically small proteins of low molecular weight and other drug molecules that
do not elicit an immune response on their own. Some of the most significant
advantages of this molecule as a carrier protein are its established track
record of being extremely safe in the human body, an exceptionally large
molecular size with numerous epitope (the part of an antigen that is recognized
by the immune system) binding sites for maximized antigen conjugation, and a
proven ability to function as a high-efficiency carrier in multiple different
applications.
With the granting of an FDA
Breakthrough Therapy Designation for a KLH-based immunotherapy compound earlier
this year in March, developed by Celldex Therapeutics (NASDAQ: CLDX), which is
studying its application in adults suffering from a type of brain cancer known
as GBM (EGFRvIII-positive glioblastoma), Stellar Biotechnologies (OTC: SBOTF)
(TSXV: KLH) is now extremely well positioned, given that this will likely turn
out to be one of the historically most important milestones for validating the
KLH-conjugate approach in immunotherapy. The company is aggressively moving to
strengthen its overall market presence and really capitalize on the emerging
realization throughout the industry of the vast potential of this
immune-stimulating protein, and its potential applications across a whole host
of immunotherapeutic markets.
The company has now announced a
crucial move to up-sell KLH into said markets through a greatly expanded online
presence, pushing the company’s corporate communications channels further out
into the realm of social media, with a concerted effort to provide the relevant
educational content and information about Stellar’s game-changing technology,
as well as keeping everyone updated on the company’s constant innovations and
activities. The plan is to branch out from the main corporate site
www.stellarbiotech.com, leveraging the enormous wealth of scientific and
clinical data compiled at www.klhsite.org, in order to establish a bold presence
across the three main social media vectors. Google’s (NASDAQ: GOOGL) rapidly
growing Google+ framework, which is arguably one of the best ways to increase
search visibility in the business world due to its native dovetailing with
Google’s ever-changing algorithms, via the “+StellarBiotech” handle, as well as
through the still enormously popular venue Facebook (NASDAQ:FB) via the
company’s www.facebook.com/StellarBiotech page, and of course by using Twitter
(NYSE:TWTR), via their @StellarBiotech account.
Keeping investors and key
industry players alike up to date through consistent communication of the
company’s activities, as well as routinely pushing relevant data regarding
industry developments and the important role Stellar’s KLH technology plays, will
no doubt be fundamentally important to the company’s overall marketing
strategy. Investors should keep a close eye on Stellar Biotechnologies as their
social media footprint takes shape and KLH cements an increasingly frontline
role in immunotherapy.
For more information, visit
www.stellarbiotechnologies.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
